



Wednesday, 30 September 2015 14:43 GMT

KEYWORDS : *GBA GENERIC DRUG SPEND HTA IQWIG INSURANCE PAYER PRICING*

Pharma, payers begin talks over Germany's AMNOG drug pricing law

BERLIN, Sep 30 (APM) - German payers and pharma have entered into talks about the country's drug-pricing AMNOG laws, representatives of both branded and generic pharma in the country announced on Wednesday.

In a short statement, branded pharma bodies BPI and vfa, as well as Pro Generika and manufacturers' association BAH, said they would discuss negotiations on the AMNOG - which guides individual drug prices within Germany's 35.4 billion euro annual drug spend - with umbrella payer group GKV-Spitzenverband. GKV-SV was not itself a signatory to the statement.

Talks started today, but the announcement comes at a time when all parties have repeatedly voiced their side of the pricing debate (APMHE 44257), (APMHE 44224), (APMHE 44141).

More to follow.

cf/clg

catherine.featherston@apmnews.com

[44283] 30/09/2015 14:43 GMT

©2005-2015 APM Health Europe.